Single Nucleotide Polymorphisms: Impact on Susceptibility to Chemotherapy in Patients with Colorectal Cancer

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2024 Nov 22

PMID 39576003

Authors

M Angeles Vaz-Salgado

Victor Albarran

Javier Pozas

Reyes Ferreiro

Vanessa Pachon

Federico Longo

Mercedes Rodriguez

Emma Barreto

Julie Earl

Affiliations

Soon will be listed here.

Abstract

Background: Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.

Materials & Methods: A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.

Results: SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.

Conclusion: Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.

References

Zhu H, Yuan S, Fang Y, Sun X, Kong H, Ge W . The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J. 2010; 11(3):237-46. DOI: 10.1038/tpj.2010.26. View

Fernandez-Rozadilla C, Timofeeva M, Chen Z, Law P, Thomas M, Schmit S . Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet. 2022; 55(1):89-99. PMC: 10094749. DOI: 10.1038/s41588-022-01222-9. View

Maughan T, Adams R, Smith C, Meade A, Seymour M, Wilson R . Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377(9783):2103-14. PMC: 3159415. DOI: 10.1016/S0140-6736(11)60613-2. View

Sameer A . Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013; 3:114. PMC: 3651991. DOI: 10.3389/fonc.2013.00114. View

Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H . A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative. Rep Biochem Mol Biol. 2018; 7(1):30-37. PMC: 6175593. View

Mango K, Kiss A, Fekete F, Erdos R, Monostory K . CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function. Sci Rep. 2022; 12(1):2984. PMC: 8863776. DOI: 10.1038/s41598-022-07022-9. View

Cheng S, Chen N, Wen Z, Yao Z, Tsui K, Kuo H . Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells. Int J Mol Sci. 2021; 22(13). PMC: 8268701. DOI: 10.3390/ijms22137080. View

Jennings B, Willis G . How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy. Cancer Lett. 2014; 356(2 Pt A):224-30. DOI: 10.1016/j.canlet.2014.02.024. View

Jomura R, Akanuma S, Tachikawa M, Hosoya K . SLC6A and SLC16A family of transporters: Contribution to transport of creatine and creatine precursors in creatine biosynthesis and distribution. Biochim Biophys Acta Biomembr. 2021; 1864(3):183840. DOI: 10.1016/j.bbamem.2021.183840. View

10.

Shen X, Wang J, Yan X, Ren X, Wang F, Chen X . Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2016; 77(6):1285-302. DOI: 10.1007/s00280-016-3047-1. View

11.

Afzal S, Jensen S, Vainer B, Vogel U, Matsen J, Sorensen J . MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009; 20(10):1660-6. DOI: 10.1093/annonc/mdp046. View

12.

Jacob C, Pastorino A, Okay T, Castro A, Gushken A, Watanabe L . Interleukin 10 (IL10) and transforming growth factor β1 (TGFβ1) gene polymorphisms in persistent IgE-mediated cow's milk allergy. Clinics (Sao Paulo). 2013; 68(7):1004-9. PMC: 3714916. DOI: 10.6061/clinics/2013(07)19. View

13.

Zintzaras E, Ziogas D, Kitsios G, Papathanasiou A, Lau J, Raman G . MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics. 2009; 10(8):1285-94. DOI: 10.2217/pgs.09.59. View

14.

Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V . Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006; 79(6):570-80. DOI: 10.1016/j.clpt.2006.02.003. View

15.

Cui J, Li G, Yin J, Li L, Tan Y, Wei H . GSTP1 and cancer: Expression, methylation, polymorphisms and signaling (Review). Int J Oncol. 2020; 56(4):867-878. DOI: 10.3892/ijo.2020.4979. View

16.

Carr D, Chaponda M, Cornejo Castro E, Jorgensen A, Khoo S, van Oosterhout J . CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. J Antimicrob Chemother. 2014; 69(12):3329-34. PMC: 4228781. DOI: 10.1093/jac/dku315. View

17.

Wang B, Liu Z, Xu W, Sun S . CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression. Tumour Biol. 2013; 34(4):2357-66. DOI: 10.1007/s13277-013-0783-2. View

18.

Pardini B, Kumar R, Naccarati A, Novotny J, Prasad R, Forsti A . 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011; 72(1):162-3. PMC: 3141199. DOI: 10.1111/j.1365-2125.2010.03892.x. View

19.

Paula D, do Brasil Costa V, Jorge R, Nobre F . Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer. Support Care Cancer. 2019; 28(1):395-403. DOI: 10.1007/s00520-019-04841-x. View

20.

Li Q, Shu Y . Role of solute carriers in response to anticancer drugs. Mol Cell Ther. 2015; 2:15. PMC: 4452062. View